| Patents and the experimental space: Social, legal and geographical dimensions of 3D bioprinting E Bicudo, A Faulkner, P Li International Review of Law, Computers & Technology 35 (1), 2-23, 2021 | 16 | 2021 |
| Pharmaceutical research, democracy and conspiracy: International clinical trials in local medical institutions E Bicudo Routledge, 2016 | 13 | 2016 |
| Digital readiness in 3D bioprinting: software, governance and hospitals’ proto-clinical interfaces E Bicudo, A Faulkner, P Li Regenerative medicine 16 (03), 237-252, 2021 | 12 | 2021 |
| The UK’s emerging regulatory framework for point-of-care manufacture: insights from a workshop on advanced therapies E Bicudo, I Brass, P Carmichael, S Farid Cell and Gene Therapy Insights 7 (9), 1005-1015, 2021 | 11 | 2021 |
| Software, risks, and liabilities: ongoing and emergent issues in 3D bioprinting E Bicudo, A Faulkner, P Li Journal of Risk Research 24 (10), 1319-1334, 2021 | 11 | 2021 |
| Sociotechnical alignment in biomedicine: The 3D bioprinting market beyond technology convergence E Bicudo, A Faulkner, P Li Technology in Society 66, 101668, 2021 | 9 | 2021 |
| The active role of geography: a manifesto A Bernardes, A Zerbini, C Gomes, E Bicudo, E Almeida, FB Contel, ... Antipode 49 (4), 952-958, 2017 | 9 | 2017 |
| " Geographical randomization" and" Social exploitation" in clinical research: World trials in Santiago, Chile. E Bicudo Health & place, 2011 | 9 | 2011 |
| Psicoesfera e medicina: meio construído urbano e congressos médicos na América Latina EP Almeida, E Bicudo Revista geográfica venezolana 51 (2), 179-201, 2010 | 8 | 2010 |
| O circuito superior marginal: produção de medicamentos e o território brasileiro EC Bicudo Junior Universidade de São Paulo, 2006 | 8 | 2006 |
| Genomics politics through space and time: the case of bioinformatics in Brazil E Bicudo Public health genomics 19 (2), 81-92, 2016 | 7 | 2016 |
| Patent power in biomedical innovation: Technology governance in biomodifying technologies E Bicudo, M Morrison, P Li, A Faulkner, A Webster, M Mourby, J Kaye The Journal of World Intellectual Property 25 (2), 473-494, 2022 | 6 | 2022 |
| Biomodifying the ‘natural’: from adaptive regulation to adaptive societal governance M Mourby, J Bell, M Morrison, A Faulkner, P Li, E Bicudo, A Webster, ... Journal of Law and the Biosciences 9 (1), lsac018, 2022 | 5 | 2022 |
| ‘Big data’or ‘big knowledge’? Brazilian genomics and the process of academic marketization E Bicudo BioSocieties 13 (1), 1-20, 2018 | 5 | 2018 |
| Institutional and infrastructure challenges for hospitals producing advanced therapies in the UK: the concept of ‘point-of-care manufacturing readiness’ E Bicudo, I Brass Regenerative medicine 17 (10), 719-737, 2022 | 4 | 2022 |
| Biomodifying technologies and experimental space: organisational and regulatory implications for the translation and valuation of health research.-ESRC M Morrison, M Mourby, A Bartlett, E Bicudo Impact 2019 (1), 63-65, 2019 | 4 | 2019 |
| Globalization and ideology: Ethics committees and global clinical trials in South Africa and Brazil E Bicudo | 2 | 2012 |
| Sistemas de ações e o meio construído urbano: Por uma geografia dos possíveis E BICUDO Anais do X Encontro de Geógrafos da América Latina, 2005 | 2 | 2005 |
| Advanced therapies, hospital exemptions & marketing authorizations: the UK’s emerging regulatory framework for point-of-care manufacture E Bicudo, I Brass Cell & Gene Therapy Insights 9 (1), 101-120, 2023 | 1 | 2023 |
| Point-of-care manufacture of advanced therapies: readiness measures for hospitals, companies, and regulatory agencies E Bicudo, I Brass, P Carmichael Future Targeted Healthcare Manufacturing Hub, UCL, 2022 | 1 | 2022 |
